Plain-English translation of NCT05652439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is comparing the safety of BDP/FF/GB—a three-in-one inhaler medication for COPD (chronic obstructive pulmonary disease)—when delivered through two different types of devices: a dry powder inhaler (DPI) and a pressurized metered-dose inhaler (pMDI). The study will track whether either device is safer for your heart and brain by reviewing medical records from patients across seven European countries.
After a new medication is approved and widely used, it's important to keep watching for any unexpected side effects, especially serious ones affecting the heart or brain. This study wants to make sure both inhaler devices deliver this medication safely over time.
You likely qualify if…
You likely don't qualify if…
You would not visit a clinic or take any new medication for this study. Instead, researchers would review your existing medical records over time to track whether you have any heart or stroke events while using your inhaler. The study follows you from when you start the medication until you stop taking it, switch to a different medication, or the study ends—researchers simply observe and record what happens as part of your normal medical care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United Kingdom